generations of glp 1 agonists Frontiers List of current GLP-1 and
Description
Liver transaminases were significantly reduced after 12 months of PIO therapy, as well as after combination therapy
[DOI] [PMC free article] [PubMed] [Google Scholar] 48
GLP-1Ra at doses intended for T2D management Studies have examined the risk of fracture in both obese and non-obese individuals taking GLP-1Ra at doses intended for T2D (such as liraglutide 1.2 mg daily versus 3.0 mg daily for obesity) [75,76,77]
The USA shows growth at 5.2%, reflecting a mature healthcare market but strong demand for advanced treatments
These drugs work by acting on different hormones that help regulate weight, insulin levels and craving centers in the brain
Overall, GLP-1 RAs have a favourable safety profile, with benefits that significantly outweigh their manageable side effects
